Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients

Eur J Surg Oncol. 2008 Apr;34(4):462-8. doi: 10.1016/j.ejso.2007.06.006. Epub 2007 Aug 20.

Abstract

Objective: To evaluate the impact of surgery as first-line treatment on event-free survival (EFS) of primary aggressive fibromatosis.

Patients and methods: Treatments were categorized into: surgery with or without radiotherapy and nonsurgical strategies with systemic treatment alone or wait and see policy. Eighty-nine patients had initial resection of their primary tumour followed by postoperative radiotherapy in 13 cases. Twenty-three did not undergo surgery but received systemic treatment or watch and wait policy.

Results: Median follow-up was 76 months. Overall 3 years EFS was 49%. In the univariate analysis, patients with microscopically complete surgery had a similar outcome to patients in the no-surgery group (3 years EFS of 65% and 68%, respectively). Gender, age, tumour size, treatment period and strategy (surgery versus no-surgery) were not statistically significant. Quality of resection according to margins and the tumour site were the only prognostic factors. There was a significant correlation between tumour site and quality of surgery (p=0.0002).

Conclusions: A subset of patients with extra-abdominal fibromatosis could be managed with a nonaggressive policy, as growth arrest concerned 2/3 of nonoperated patients. When surgery is finally necessary, it should be performed with the aim of achieving negative margins.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Fibromatosis, Aggressive / pathology
  • Fibromatosis, Aggressive / surgery*
  • Fibromatosis, Aggressive / therapy
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Radiotherapy, Adjuvant
  • Soft Tissue Neoplasms / pathology
  • Soft Tissue Neoplasms / surgery*
  • Soft Tissue Neoplasms / therapy
  • Survival Analysis

Substances

  • Antineoplastic Agents